Galderma Unveils Promising Data on Injectable Aesthetics at ASDS 2025

Galderma recently presented significant new data from its innovative injectable aesthetics portfolio at the American Society for Dermatologic Surgery (ASDS) 2025 Annual Meeting in Chicago. The presentations highlighted advancements in Restylane, Sculptra, and Relfydess, underscoring Galderma's commitment to scientific innovation and practitioner education in the field of dermatology.

Key Takeaways

• New data showcased the versatility of Restylane injectables for chin profile enhancement, temple volume restoration, and décolletage skin quality improvement.

• Sculptra, in combination with Restylane Lyft or Contour, demonstrated sustained aesthetic facial improvements for patients experiencing volume loss after medication-driven weight loss.

• Investigational Relfydess (RelabotulinumtoxinA) showed rapid onset and long duration of effect for frown lines and crow's feet.

• Galderma also hosted educational sessions focusing on its Alastin skincare brand.

Advancements in Restylane Portfolio

Galderma's Restylane line of hyaluronic acid (HA) injectables demonstrated impressive results across several applications. Pivotal study data revealed that Restylane Lyft effectively improved chin profiles in patients with mild to moderate chin retrusion, with high patient and investigator satisfaction reported. The treatment also showed sustained aesthetic improvements in the lower face and jawline appearance.

Furthermore, Restylane Skinboosters showed significant improvements in décolletage wrinkles and skin hydration, with high response rates sustained over several months. Restylane Contour was effective in restoring temple volume, providing long-lasting and natural-looking results.

Sculptra and Weight Loss-Related Volume Loss

New phase IV study results presented at ASDS 2025 highlighted the efficacy of Sculptra, a regenerative biostimulator, when used in a treatment regimen with Restylane Lyft or Restylane Contour. This combination effectively addressed facial wrinkles and contour deficiencies in patients experiencing volume loss due to medication-driven weight loss. The treatment regimen supported collagen and elastin production, leading to lasting improvements in skin radiance and hydration, with high patient satisfaction reported.

Promising Pipeline Data for Relfydess

Phase III data for the investigational product Relfydess (RelabotulinumtoxinA) indicated a rapid onset of action as early as day one, with sustained effects on frown lines and crow's feet for over six months. Patient satisfaction remained high throughout the study period, and the treatment was well-tolerated.

Commitment to Education and Innovation

Galderma's presence at ASDS 2025 also included educational events through the Galderma Aesthetic Injector Network (GAIN). These sessions, along with expert-led discussions on emerging patient profiles like those experiencing volume loss from GLP-1 medications, reinforced Galderma's dedication to advancing aesthetic medicine through science-backed solutions and comprehensive practitioner education.

Sources

• ASDS 2025: Compelling New Data on Restylane, Sculptra and Relfydess Highlight Galderma’s InnovativeInjectable Aesthetics Portfolio and Pipeline, BioSpace.